Evidence map›Paper›PMID 30564523›Full record

ArticlePeerJ2018

Association of urinary activity of MMP-9 with renal impairment in Mexican patients with type 2 diabetes mellitus.

Alan Uriel García-Tejeda, Clara Luz Sampieri, Irene Suárez-Torres, Jaime Morales-Romero, Verónica Patricia Demeneghi-Marini, Magda Elena Hernández-Hernández, Arturo Rodríguez-Hernández

Open access · goldAbstract read
In one paragraph

Article in PeerJ, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Novel Cardiovascular Risk Factors in Patients with Diabetic Kidney Disease.International journal of molecular sciences · 2021
    Review
  3. Review
  4. Accelerated Kidney Aging in Diabetes Mellitus.Oxidative medicine and cellular longevity · 2020
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Alan Uriel García-Tejeda *Instituto de Salud Pública, Universidad Veracruzana, Xalapa, Veracruz, México.
Clara Luz Sampieri *Instituto de Salud Pública, Universidad Veracruzana, Xalapa, Veracruz, México.ORCID 0000-0003-0283-0916
Irene Suárez-TorresInstituto de Salud Pública, Universidad Veracruzana, Xalapa, Veracruz, México.
Jaime Morales-RomeroInstituto de Salud Pública, Universidad Veracruzana, Xalapa, Veracruz, México.
Verónica Patricia Demeneghi-MariniInstituto Mexicano del Seguro Social, Unidad de Medicina Familiar No. 66. Delegación Veracruz Norte, Xalapa, Veracruz, México.
Magda Elena Hernández-HernándezSecretaría de Salud del Estado de Veracruz, Unidad de Inteligencia Epidemiológica en Salud, Xalapa, Veracruz, México.
Arturo Rodríguez-HernándezInstituto Mexicano del Seguro Social, Unidad de Medicina Familiar No. 10, Xalapa, Veracruz, México.
Universidad Veracruzana · MXMexican Social Security Institute · MXSecretaria de Salud · HN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDiabetic kidney disease is the most common cause of chronic kidney disease (CKD). An early event in diabetic kidney disease is alteration of the glomerular basement membrane and the mesangial expansion. Matrix metalloproteinases (MMP) are a family of endopeptidases responsible for controlling the pathophysiological remodeling of tissues, including renal tissues. MMP-9 in human urine has been proposed as a marker of diabetic nephropathy and urinary tract infections (UTI).

methodsA cross-sectional study was conducted in type 2 diabetes mellitus (T2DM) patients who receive first level medical attention in Mexico. We used ELISA to measure MMP-9 levels in the urine of subjects with T2DM ≥ 18 years of age, who fulfilled the clinical requirements for calculation of glomerular filtration rate (GFR), according to the K/DOQI guide, in an attempt to identify whether MMP-9 levels in T2DM differ in patients with and without renal impairment. Univariate and multivariable analyses were performed in order to identify the association between MMP-9 and renal impairment.

resultsIncluded in the study were 34 (45%) subjects with renal impairment and 42 (55%) without. In the group with renal impairment, 10 subjects corresponded to stages 1-2 and 24 subjects corresponded to stage 3, according to their values of GFR and urinary albumin, following that proposed by the K/DOQI. No differences were found relating to sex, age, having or not having a partner, education, being able to read and write a message and duration of T2DM. Moreover, no differences were found between the groups in terms of weight, height, body mass index, waist size in general and frequency of UTI. In contrast, serum creatinine and urinary albumin were higher in the group with renal impairment, while GFR was greater in the group without renal impairment. Levels of MMP-9 were greater in women compared to men. Through univariate analysis in the general population, the presence of MMP-9 and that of its percentile 90 (P DISCUSSION: It is necessary to validate sensitive and non-invasive biological markers of CKD. We demonstrate that the presence and P

Indexed as

Matrix metalloproteinasesRenal impairmentType 2 diabetes mellitusUrine MMP-9

Identifiers

PMID30564523
PMCPMC6286807
OpenAlexW2903561540

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.